FOLH1 and posterior cortical atrophy: The literature showed that the local control of disease after SBRT based on PSMA-PET or metastatic direct therapy (MDT) based on PSMA-PET in patients with oligometastatic or oligo recurrent PCa at 1 year is 100% [25], ranging between 92 and 96% at 2 years ([19,20,21]), and 55% at 3 years [32].